ArticleJournal of medical biochemistry2026
Diagnostic and prognostic value of serum markers CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 in colon cancer.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess the clinical utility of serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50, CA19-9, CA72-4, and the cytokeratin 19 fragment (CYFRA21-1) - for early detection and prognostic evaluation in colon cancer. Methods: A total of 50 patients diagnosed with colon cancer and 50 healthy individuals were enrolled. Serum levels of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 were quantified and compared between groups. Correlations with tumour staging, recurrence, and metastasis were also analysed. Results: All five serum markers were significantly elevated in colon cancer patients compared to controls (P< 0.05). Marker levels were notably higher in advanced-stage cases (stages III-IV) than in early-stage disease (stages I-II) (P< 0.05). Following surgery, marker levels declined significantly (P< 0.05), except in patients with recurrence or metastasis, who showed elevated preoperative values (P< 0.05). Combined detection yielded significantly higher positive detection rates, sensitivity, and specificity than individual marker assessments (P< 0.05). Conclusions: CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 are clinically relevant markers for the detection, staging, and prognostic prediction of colon cancer. Combined serum marker analysis substantially improves diagnostic precision and supports early screening and outcome assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.